688566.SH
吉贝尔
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 25.41
−3.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 990.7M | 966.1M | 896.5M | 860.9M | 654.7M |
| Cost of Revenue | 103.1M | 101.8M | 95.3M | 95.2M | 76.2M |
| Gross Profit | 887.6M | 864.2M | 801.3M | 765.8M | 578.6M |
| Operating Expenses | |||||
| R&D Expense | 42.5M | 40.7M | 38.7M | 55.8M | 55.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 81.1M | 72.1M | 61.5M | 58.0M | 50.6M |
| Selling & Marketing Expense | 510.8M | 490.9M | 397.0M | 401.9M | 310.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 645.8M | 614.4M | 505.0M | 514.3M | 414.3M |
| Cost and Expenses | 748.9M | 716.3M | 600.3M | 609.5M | 490.5M |
| Operating Income (EBIT) | 247.5M | 254.1M | 254.7M | 249.1M | 176.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 294.2M | 301.1M | 253.4M | 247.5M | 174.5M |
| Income Tax Expense | 41.7M | 40.1M | 34.4M | 28.7M | 20.3M |
| Bottom Line | |||||
| Net Income | 254.1M | 261.6M | 219.3M | 219.1M | 154.7M |
| Earnings from Cont. Ops | 252.5M | 261.0M | 219.0M | 218.8M | 154.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 254.1M | 261.6M | 219.3M | 219.1M | 154.7M |
| Per Share | |||||
| Basic EPS | CN¥1.27 | CN¥1.31 | CN¥1.13 | CN¥1.17 | CN¥0.83 |
| Diluted EPS | CN¥1.27 | CN¥1.31 | CN¥1.13 | CN¥1.17 | CN¥0.83 |
| Revenue Per Share | CN¥4.95 | CN¥4.84 | CN¥4.62 | CN¥4.60 | CN¥3.51 |
| Shares | |||||
| Basic Shares Outstanding | 200.0M | 199.7M | 194.1M | 187.3M | 186.3M |
| Diluted Shares Outstanding | 200.0M | 199.7M | 194.1M | 187.3M | 186.3M |
| Profitability Metrics | |||||
| EBITDA | — | 272.5M | 266.2M | 261.4M | 190.2M |
| D&A | — | 18.5M | 11.5M | 12.3M | 13.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026